Key facts for Q5172
- Billing unit
- 1 MCG
- Inj, filkri, 1 mcg
- OPPS payment rate
- $0.74
- no ASP limit; SI K, October 2026
- Practitioner MUE
- none published
- CMS publishes no MUE for this code
- NCCI exposure
- no PTP pairs
- Coverage articles
- 0
- none list this code
TL;DR
HCPCS Q5172 is the Level II code for Injection, filgrastim-laha (filkri), biosimilar, 1 microgram, billed per 1 MCG. CMS publishes no ASP payment limit for it; hospital outpatient departments are paid separately under OPPS (status indicator K, $0.74 per billing unit in October 2026). As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. Other HCPCS codes whose descriptor names filgrastim: Q5148 (biosimilar filgrastim-txid (Nypozi)); Q5125 (biosimilar filgrastim-ayow (Releuko) from Amneal Pharmaceuticals, LLC); Q5110 (biosimilar filgrastim-aafi (Nivestym) from Pfizer Inc); Q5101 (biosimilar filgrastim-sndz (Zarxio) from Sandoz Inc); J1442 (non-biosimilar filgrastim (Neupogen) from Amgen Inc). The OPPS crosswalk maps 1 NDC to it, sold as Filkri by Accord BioPharma, Inc. No current Billing and Coding Article lists Q5172, so coverage follows the FDA label, compendia and any applicable NCD.
Medicare payment: OPPS rate (no ASP limit)
Q5172 does not appear in the October 2026 Part B ASP payment limit file. CMS pays it separately to hospital outpatient departments under OPPS with status indicator K in APC 0973, at a national unadjusted rate of $0.74 per 1 MCG. Status K is a separately paid, non-pass-through drug or biological, including therapeutic radiopharmaceuticals. In a physician office the Medicare contractor prices the drug, often from invoice; commercial and Medicaid payers set their own rates.
NDC to HCPCS billing-unit conversion
The October 2026 OPPS crosswalk maps 1 NDC from 1 labeler to Q5172. Report the NDC in the claim's drug segment and bill the number of Q5172 units that equals the quantity administered divided by 1 MCG; the last column gives units per full package.
| NDC | Drug name | Labeler | Package size | Billing units / package |
|---|---|---|---|---|
| 69448-0008-63 | Filkri | Accord BioPharma, Inc | 0.5 × 1 | 300 |
Medically Unlikely Edits (MUE)
CMS does not publish an MUE for Q5172 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.
MUE for Q5172 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
No active practitioner PTP pair lists Q5172 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.
The counts above are exposure, not answers for a specific claim. Check Q5172 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
Q5172 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
No current Billing and Coding Article lists Q5172 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, Q5172 carries status indicator K and is assigned to APC 0973, with a published national unadjusted payment of $0.74. Status K means the drug is paid separately under OPPS rather than packaged into the procedure.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), Q5172 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $0.74 per 1 MCG, paid only when the drug is furnished integral to a covered surgical procedure.
Common denials for Q5172 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for Q5172
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- October 2026 HCPCS update report: Q5172 was added in the October 2026 HCPCS update.
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS Q5172
What does HCPCS code Q5172 describe?
Q5172 is defined by CMS as "Injection, filgrastim-laha (filkri), biosimilar, 1 microgram". Each billing unit represents 1 MCG, so the units reported on the claim must equal the dose administered divided by that unit.
Is Q5172 a CPT code?
No. Q5172 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as filgrastim-laha (Filkri); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5172 reports the drug itself in 1 mcg units, and the administration is billed on its own line.
What does Medicare pay for Q5172 in a hospital outpatient department?
Q5172 has no Part B ASP limit; the October 2026 OPPS Addendum B pays it separately under status K, APC 0973, at $0.74 per 1 MCG, and ASC Addendum BB gives it payment indicator K2 at $0.74.
Which NDCs map to Q5172?
The October 2026 OPPS crosswalk lists 1 NDC from 1 labeler: Filkri (Accord BioPharma, Inc). For example NDC 69448-0008-63 (package size 0.5) equals 300 billing units of Q5172.
Does Q5172 have NCCI bundling edits?
No active practitioner PTP pairs list Q5172 as a column-1 or column-2 code in the v323r0 release.
Q5172 vs Q5148: what is the difference?
Both are HCPCS Level II codes whose descriptor names filgrastim. What sets Q5148 apart: biosimilar filgrastim-txid (Nypozi). Q5172 is billed per 1 mcg, OPPS rate $0.74; Q5148 is billed per 1 mcg, limit $1.026, MUE 1500. Report the code whose descriptor matches the product and setting in the record.
Q5172 vs Q5125: what is the difference?
Both are HCPCS Level II codes whose descriptor names filgrastim. What sets Q5125 apart: biosimilar filgrastim-ayow (Releuko) from Amneal Pharmaceuticals, LLC. Q5172 is billed per 1 mcg, OPPS rate $0.74; Q5125 is billed per 1 mcg, limit $0.308, MUE 1800. Report the code whose descriptor matches the product and setting in the record.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- OPPS NDC-HCPCS crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 OPPS NDC-HCPCS Crosswalk 090426.csvSHA-256 167efe9e47c42718…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.